Advertisement

European Journal of Clinical Pharmacology

, Volume 28, Issue 2, pp 113–117 | Cite as

Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise

  • M. R. Wilkins
  • K. L. Woods
  • D. B. Jack
  • M. J. Kendall
  • S. J. Laugher
Originals

Summary

In a placebo controlled exercise protocol using healthy volunteers the effects of nadolol 80 mg and 160 mg orally and of nadolol 80 mg during treatment with nifedipine 20 mg 8 hourly were compared. Resting systolic and diastolic blood pressures were reduced by both nifedipine (p<0.05) and nadolol (p<0.01) acting alone. An unexpected finding was that nifedipine alone significantly inhibited exercise tachycardia (p<0.01) (8 to 12 h post dose). Predictably both doses of nadolol produced significant reduction in exercise tachycardia which was still apparent at 24 h. There was a linear relationship between log10 plasma nadolol concentration and reduction in exercise heart rate. The combined inhibitory effects of nifedipine and nadolol 80 mg on exercise heart rate showed partial additivity but did not summate. There was no pharmacokinetic interaction between the 2 drugs. The inhibition of exercise tachycardia by nifedipine, not previously documented, is consistent with an effect of the drug on the sinus node, as has been reported in in-vitro studies, and may contribute to the drugs efficacy in angina.

Key words

nadolol nifedipine tachycardia cardiovascular response healthy volunteers pharmacokinetics exercise heart rate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Opie LH, Jee L, White D (1982) Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol. Am Heart J 104: 606–6112Google Scholar
  2. 2.
    Winniford MD, Markham RV Jr, Firth BG, Nicod P, Hillis LD (1982) Hemodynamic and electrophysiologic effects of verapamil and nifedipine in patients on propranolol. Am J Cardiol 50: 704–710Google Scholar
  3. 3.
    Leon MB (1983) Combination therapy using calcium-channel blockers and beta-blockers in patients with chronic stable angina pectoris. Carciovasc Rev Rep 4: 171–177Google Scholar
  4. 4.
    Dargie HJ, Lynch PG, Krikler DM, Harris L, Krikler S (1981) Nifedipine and propranolol: a beneficial drug interaction. Am J Med 71: 676–682Google Scholar
  5. 5.
    Opie LH (1984) Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review. Q J Med 209: 1–16Google Scholar
  6. 6.
    Singh BN (1983) The pharmacology of slow-channel blocking drugs. Cardiovasc Rev Rep 4: 179–192Google Scholar
  7. 7.
    Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle. Wiley New YorkGoogle Scholar
  8. 8.
    Frishman WH (1981) Nadolol a new β-adrenoreceptor antagonist. N Engl J Med 305: 678–682Google Scholar
  9. 9.
    Scales B, Copsey PB (1975) The gas chromatographic determination of atenolol in biological samples. J Pharm Pharmacol 27: 430–433Google Scholar
  10. 10.
    Jack DB, Quarterman CP, Zaman R, Kendall MJ (1982) Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol 23: 37–42Google Scholar
  11. 11.
    Jack DB, Kendall MJ, Dean S, Laugher SJ, Zaman R, Tenneson ME (1982) The effect of hydallazine on the pharmacokinetics of three different beta-adrenoceptor antagonists. Biopharm Drug Dispos 3: 47–54Google Scholar
  12. 12.
    Pedersen OL, Christensen CK, Mikkelsen E, Ramsch KD (1980) Relationship between the antihypertensive effect and steady-state plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. Eur J Clin Pharmacol 18: 287–293Google Scholar
  13. 13.
    Ning W, Wit AL (1983) Comparison of the direct effects of nifedipine and verapamil on the electrical activity of the sinoatrial and atrioventricular nodes of the rabbit heart. Am Heart J 106: 345–355Google Scholar
  14. 14.
    MacGregor GA, Rotellar C, Markandu ND, Smith SJ, Sagnella GA (1982) Contrasting effects of nifedipine, captopril and propranolol in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 4: S358–362Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • M. R. Wilkins
    • 1
  • K. L. Woods
    • 1
  • D. B. Jack
    • 1
  • M. J. Kendall
    • 1
  • S. J. Laugher
    • 1
  1. 1.Department of TherapeuticsMedical SchoolBirminghamEngland

Personalised recommendations